We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





LumiraDx Presents LumiraDx Point of Care Instrument at IFCC EUROMEDLAB

By LabMedica International staff writers
Posted on 11 Apr 2022

LumiraDx (London, UK) participated in the IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine (EUROMEDLAB) hosted by the German Society of Clinical Chemistry and Laboratory Medicine (DGKL), one of the oldest national societies devoted to clinical chemistry and laboratory medicine. More...

EUROMEDLAB 2022 combined a large scientific program with educational workshops and symposia providing cutting edge science and breakthrough technologies. Alongside this, there was an industry exhibition showcasing the latest innovations in the field of clinical chemistry, diagnostics, clinical microbiology and laboratory informatics.

LumiraDx exhibited at EUROMEDLAB live for the first time to present its LumiraDx point of care instrument which offers a broad menu of lab-comparable results on a single, portable diagnostic platform. The LumiraDx Platform is an innovative, next generation point of care diagnostic system that combines a small, portable instrument, advanced low cost test strip and seamless secure digital connectivity to the Cloud and hospital IT systems. The LumiraDx Platform and tests are designed on the same principles as lab analyzer systems, to deliver accurate results compared to laboratory reference assays across a number of parameters, in a portable, easy-to-use point of care solution. Easy and intuitive to use, it requires only basic training and is designed to be affordable and accessible at the point of care. The platform is designed to go wherever the patient is, whether this is in a hospital, medical office, pharmacy, or in other non-traditional settings such as schools or airports.

The LumiraDx Platform menu includes point of care tests for COVID-19 Antibody, INR and D-Dimer - with high levels of accuracy comparable to central lab-based tests - all of which have achieved CE Mark and are commercially available in Europe. LumiraDx has also developed a high sensitivity antigen test for COVID-19 on the LumiraDx Platform. The LumiraDx COVID-19 antigen test has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) and achieved CE Mark. The LumiraDx Platform and COVID-19 antigen tests are also available in Japan and Brazil and has been rolled out in more than 60 countries globally.

Related Links:
LumiraDx 


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.